Original Articles

You have full text access to this OnlineOpen article

Decision analysis model for hepatitis B prophylaxis one year after liver transplantation

Sammy Saab^1,2,†,*,
Maggie Y. Ham¹,
Michael A. Stone¹,
Curtis Holt²,
Myron Tong^1,2,3

Article first published online: 26 MAR 2009

DOI: 10.1002/lt.21712

Issue

Liver Transplantation

Volume 15, Issue 4, pages 413–420, April 2009

Additional Information

How to Cite

Saab, S., Ham, M. Y., Stone, M. A., Holt, C. and Tong, M. (2009), Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl, 15: 413–420. doi: 10.1002/lt.21712

Author Information

¹
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
²
Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
³
Huntington Medical Research Institutes, Pasadena, CA

^†
Telephone: 310-206-6705; FAX: 310-206-4197

Email: Sammy Saab (ssaab@mednet.ucla.edu)

^*Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095

^†
Telephone: 310-206-6705; FAX: 310-206-4197

Publication History

Issue published online: 26 MAR 2009
Article first published online: 26 MAR 2009
Manuscript Accepted: 16 NOV 2008
Manuscript Received: 25 JUN 2008

ARTICLE TOOLS

View Full Article (HTML) Get PDF (182K)

REFERENCES

1
O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104–111.
2
Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650–654.
3
Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736–746.
Direct Link:
4
Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999–1002.
Direct Link:
5
Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741–748.
Direct Link:
6
Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182–187.
Direct Link:
7
Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585–589.
Direct Link:
8
Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxis of hepatitis B recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532–538.
Direct Link:
9
Coffin C, Terrault N. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007; 14: 37–44.
Direct Link:
10
Lok A. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002; 8: S67–S73.
Direct Link:
11
Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528–1535.
Direct Link:
12
Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85: 1105–1111.
13
Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890–1899.
14
Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349–360.
Direct Link:
15
Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130–2134.
Direct Link:
16
Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807–813.
Direct Link:
17
Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–313.
Direct Link:
18
Neff GW, Kemmer N, Kaiser TE, Zacharias VC, Alonzo M, Thomas M, Buell J. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497–2500.
19
Ahn J, Dodson S, Cohen, S. Oral antiviral therapy without long term maintenance hepatitis B immunoglobulin to prevent hepatitis B recurrence in liver transplant patients [abstract]. J Hepatol 2008; 48(suppl 2): S73–S74.
- CrossRef,
- Web of Science® Times Cited: 1
20
Bárcena R, Del Campo S, Moraleda G, Casanovas T, Prieto M, Buti M, et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 2005; 37: 3960–3962.
21
Gish R, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 2006; 12: S54–S64.
Direct Link:
22
Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931–937.
23
PDR Staff. Red Book. 112th ed. Montvale, NJ: Thomson Healthcare; 2008.
24
Bureau of Labor Statistics. Available at: http://www.bls.gov. Accessed November 2008.
25
Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110–1116.
Direct Link:
26
O'Carroll RE, McGregor LM, Swanson V, Masterton G, Hayes PC. Adherence to medication after liver transplantation in Scotland: a pilot study. Liver Transpl 2006; 12: 1862–1868.
Direct Link:
27
Laederach-Hofman K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry 2000; 22: 412–424.
28
Angus P, Strasser S, Patterson S, McCaughan G, Gane E. A randomized study to assess the safety and efficacy of adefovir dipivoxil substitution for hepatitis B immune globulin in liver transplantation patients receiving long-term low dose IM HBIg and lamivudine prophylaxis [abstract]. Hepatology 2007; 46: 238A.
- Web of Science® Times Cited: 6
29
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–816.
30
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.
31
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–807.
32
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.
33
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.
34
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039–2049.
35
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61–68.
36
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673–2681.
37
Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240–250.
38
Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889–896.
Direct Link:
39
Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308–312.
40
Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411–416.
Direct Link:
41
Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301–307.
42
Nikolaidis N, Vassiliadis T, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005; 19: 321–326.
Direct Link:
43
Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49–56.
Direct Link:
44
Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386–392.
Direct Link:
45
Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207–210.
Direct Link:
46
Bae SH, Yoon SK, Choi JY, Jang JW, Cho SH, Yang JM, et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2005; 20: 1527–1532.
Direct Link:
47
Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000; 6: 715–720.
Direct Link:
48
Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S, et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004; 72: 35–40.
Direct Link:
49
Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265–272.
50
Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903–910.
51
Peters MG. Diagnosis and management of hepatitis B virus and HIV coinfection. Top HIV Med 2007; 15: 163–166.
- PubMed
52
Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119: 1382–1384.
53
Stärkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001; 35: 679–681.
54
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437–1444.
55
Heathcote J, George J, Gordon S, Bronowicki J-P, Sperl J, Williams R, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J Hepatol 2008; 48(suppl 2): S32.
- CrossRef,
- Web of Science® Times Cited: 12
56
Marcellin P, Jacobson I, Habersetzer F, Senturk H, Andreone P, Moyes C, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008; 48(suppl 2): S26.
- CrossRef,
- Web of Science® Times Cited: 12
57
Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with cirrhosis. Liver Int 2008; 28: 814–820.
Direct Link:
58
van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318–325.
Direct Link:
59
Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206–210.
Direct Link:
60
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931–940.
61
Tan J, Lok A. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007; 13: 323–326.
Direct Link:

View Full Article (HTML) Get PDF (182K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Decision analysis model for hepatitis B prophylaxis one year after liver transplantation

Liver Transplantation

How to Cite

Author Information

Publication History

ARTICLE TOOLS

REFERENCES

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Decision analysis model for hepatitis B prophylaxis one year after liver transplantation

Liver Transplantation

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

REFERENCES

More content like this